Background:Numerous studies have explored the influence of XPD Lys751Gln and Asp312Asn polymorphisms on skin cancer susceptibility. However, the results remain inconclusive. To derive a more precise estimation, a meta-analysis was performed.
Methods:Electronic literature searches of the PubMed, CBM and CNKI databases were performed up to March 2014. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of the associations.
Results: Seventeen case-control studies were eligible with a total sample size of 6113 cases and 11074 controls for XPD Lys751Gln polymorphism, and 10 studies (3840cases and 7637 controls) on XPD Asp312Asn polymorphism were pooled for analysis. Overall, no significant associations were found between XPD Lys751Gln polymorphism and skin cancer risk in any genetic model. In the stratified analysis by tumor type, XPD Lys751Gln polymorphism was not associated with increased risk of nonmelanoma skin cancer, but significantly related with increased risk of cutaneous melanoma (Gln/Gln vs. Lys/Lys: OR=1.15, 95%CI=1.02-1.29, P=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, P=0.036). For XPD Asp312Asn polymorphism, no any statistical association of XPD Asp312Asn polymorphism with skin cancer risk was observed in the overall or subgroup analyses.
Conclusions: The present meta-analysis suggests that the XPD Lys751Glnpolymorphism may contribute to the risk of cutaneous melanoma from currently available evidence. Further investigations are needed to get more insight into the role of these two polymorphisms in skin carcinogenesis.
Correspondence: Dr Hong Shen (email@example.com).
This study was supported by a grant from the National Natural Science Foundation of China (No. 81271729).